Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study

BACKGROUND: Radiotherapy may synergize with programmed cell death 1 (PD1)/PD1 ligand (PD-L1) blockade. The purpose of this study was to determine the recommended phase II dose, safety/tolerability, and preliminary efficacy of combining pembrolizumab, an anti-PD1 monoclonal antibody, with hypofractio...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Sahebjam, Solmaz, Forsyth, Peter A, Tran, Nam D, Arrington, John A, Macaulay, Robert, Etame, Arnold B, Walko, Christine M, Boyle, Theresa, Peguero, Edwin N, Jaglal, Michael, Mokhtari, Sepideh, Enderling, Heiko, Raghunand, Natarajan, Gatewood, Tyra, Long, Wendy, Dzierzeski, Jennifer L, Evernden, Brittany, Robinson, Timothy, Wicklund, Melissa C, Kim, Sungjune, Thompson, Zachary J, Chen, Dung-Tsa, Chinnaiyan, Prakash, Yu, Hsiang-Hsuan Michael
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Clinical Investigations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8041351/
https://ncbi.nlm.nih.gov/pubmed/33173935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa260
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items